Bio-Techne Corp (TECH)
NASDAQ: TECHHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
TECH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $11.37B
- P/E (TTM)
- 62.53
- Forward P/E
- 31.36
- EPS (TTM)
- $1.16
- Dividend yield
- 0.44% ($0.32)
- Ex-dividend date
- Aug 24, 2026
- 52-week range
- 43.20 – 72.69
- Day range
- 72.43 – 72.55
- Volume / Avg
- 3.15M / 3.12M
- Beta
- —
- Shares outstanding
- 156.82M
- Next earnings
- Nov 4, 2026
52-week range
TECH stock today
Shares of Bio-Techne (TECH) finished higher on Oct 7 at $72.53, a gain of 0.14% or $0.10 per share, versus the S&P 500's 0.22% decline. The stock is trading at or near its 52-week high of $72.69, set on Sep 22, 2026, 67.9% above the 52-week low of $43.20. TECH is up 23.3% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 22.5%.
At 62.5x trailing earnings, Bio-Techne trades above the peer-group median of 36.5x. Its forward P/E of 31.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Bio-Techne's next earnings report is expected on Nov 4, 2026. Bio-Techne pays an annual dividend of $0.32 per share, a 0.44% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Bio-Techne
Company profileBio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Kim Kelderman
- Headquarters
- Minneapolis, MN
- Employees
- 3,000
- Website
- bio-techne.com
Financial highlights
Full financialsIn fiscal 2026, Bio-Techne generated $1.22 billion in revenue, down 0.4% from fiscal 2025, its first annual decline since 2013. Net income was $181.9 million (+147.8% year over year), for a net margin of 15.0% versus a median of 15.1% in the prior 5 years. Gross margin was 65.8% (up from 64.8%) and operating margin 20.7%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $1.22B | $1.22B | $1.16B | $1.14B | $1.11B |
| Growth | -0.38% | +5.23% | +1.97% | +2.81% | +18.75% |
| Net income | $181.86M | $73.40M | $168.10M | $285.26M | $272.05M |
| EPS (diluted) | $1.16 | $0.46 | $1.05 | $1.76 | $1.66 |
Analyst forecast
ForecastConsensus (13 analysts)
hold
Avg. price target
$70.50-2.80%
- Strong buy 0
- Buy 1
- Hold 12
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $0.40
- Last reported (Q4 2026)
- Aug 24, 2026
- EPS actual vs est.
- $0.36 vs —
Dividends
Dividend history- Annual dividend
- $0.32
- Dividend yield
- 0.44%
- Last payment
- $0.08
- Ex-dividend date
- Aug 24, 2026
TECH news
All TECH newsBio-Techne peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RGENRepligen Corporation | 167.22 | -4.37% | $10.62B | vs TECH |
| IBRXImmunityBio Inc. | 9.75 | +0.62% | $10.33B | vs TECH |
| TWSTTwist Bioscience Corporation | 155.65 | -6.78% | $10.32B | vs TECH |
| HALOHalozyme Therapeutics Inc. | 110.79 | +0.98% | $12.57B | vs TECH |
| PCVXVaxcyte Inc. | 66.96 | +0.39% | $9.96B | vs TECH |
| KRYSKrystal Biotech Inc. | 324.57 | -0.69% | $9.61B | vs TECH |
| QGENQiagen N.V. | 44.79 | -1.88% | $9.25B | vs TECH |
| KYMRKymera Therapeutics Inc. | 108.35 | +2.24% | $8.91B | vs TECH |
Indexes, lists and sector
Index membership
Appears in lists
Bio-Techne stock FAQ
What is Bio-Techne's stock price today?
TECH last traded at $72.53 as of Oct 7, 4:00 PM EDT, up 0.14% on the day. Prices are delayed at least 15 minutes.
Does Bio-Techne pay a dividend?
Yes. Bio-Techne pays $0.32 per share annually, a 0.44% yield. The most recent dividend of $0.08 had an ex-dividend date of Aug 24, 2026.
When is Bio-Techne's next earnings date?
Bio-Techne is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $0.40.
What is TECH's P/E ratio?
TECH trades at a trailing P/E ratio of 62.53 and a forward P/E of 31.36, compared with a median of 36.5 for its closest peers.
Is Bio-Techne in the S&P 500?
Yes. Bio-Techne (TECH) is a constituent of the S&P 500 index.
Who is Bio-Techne's CEO?
Mr. Kim Kelderman is the chief executive officer of Bio-Techne Corp, which has about 3,000 employees.
Has TECH ever split its stock?
Yes. The most recent TECH stock split was a 4-for-1 split on Nov 30, 2022, one of 3 splits on record.